Uncategorized Archives - Page 3 of 134

WednesdayMar 05, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Pioneers Systemic Virotherapy with RTNova Platform

Calidi’s RTNova platform leverages engineered enveloped vaccinia viruses designed for systemic delivery. Calidi’s groundbreaking virotherapy holds “immense promise in revolutionizing the treatment landscape for cancer patients with advanced solid tumors,” says CEO. Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of developing innovative immunotherapies for cancer treatment. Most recently, the company has captured the spotlight for the development of its proprietary systemic platform, RTNova (https://ibn.fm/Z4pM3). The platform represents a significant advancement in systemic virotherapy, particularly in the utilization of enveloped virotherapies to target metastatic tumors across the body. Antitumor virotherapy employs viruses that selectively infect and…

WednesdayMar 05, 2025 10:45 am

Clene Inc. (NASDAQ: CLNN) to Highlight Latest Achievements, Next Steps for CNM-Au8(R), at Q1 Virtual Investor Summit on March 11

The Q1 Virtual Investor Summit will focus on microcap companies that are undervalued, and aim to create connections between leading investors and microcap companies Clene’s presentation will be given by CEO Rob Etherington and CFO Morgan Brown Clene’s participation in the event comes as the company is moving closer to submitting a New Drug Application to the FDA to secure potential accelerated approval for CNM-Au8® for ALS The company recently partnered with German-based APST Research GmbH to analyze neurofilament light chain (“NfL”) data for evaluating CNM-Au8 efficacy in ALS patients. Clene Inc. (NASDAQ: CLNN) and its wholly owned subsidiary, Clene…

FridayFeb 28, 2025 11:00 am

Clene Inc. (NASDAQ: CLNN) Leverages APST’s NfL Database to Support FDA-Recommended Analyses for ALS Drug

Clene is partnering with APST Research GmbH to analyze neurofilament light chain (“NfL”) data for evaluating CNM-Au8® in ALS patients. APST maintains one of the largest ALS biomarker databases, with data from over 4,300 ALS patients, including clinical outcomes and biomarker tracking. The analysis will compare NfL changes in the NIH-sponsored Expanded Access Program (“EAP”) participants with historical ALS patient data to assess CNM-Au8’s potential efficacy. Clene plans to submit its statistical analysis plan to the FDA, aiming for filing of an NDA for potential accelerated approval in the second half of 2025. No significant safety concerns have been reported…

ThursdayFeb 27, 2025 10:45 am

Adageis Drives Value-Based Care Transition as Healthcare Switches from Artificial General Intelligence to Specific Use Cases

Healthcare providers are increasingly prioritizing specific, high-impact AI applications that enhance patient care and financial performance. Adageis' ProActive Care Platform leverages AI to enhance risk assessment, workflow optimization, and revenue tracking for providers. AI-driven patient monitoring and early intervention reduce hospital readmissions and improve care quality. Adageis’ Patented Risk Engine helps healthcare providers proactively address high-risk patients, improving outcomes while increasing reimbursements. Seamless integration with multiple EHR systems ensures easy adoption without disrupting provider workflows. As in other areas, artificial intelligence is making a measurable impact on healthcare, but the focus is shifting. While artificial general intelligence (“AGI”) once dominated…

TuesdayFeb 25, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth with Strengthened Financial Position and Cutting-Edge Research

One of the most significant challenges facing biotechnology companies is securing adequate funding to sustain research and development efforts. Calidi’s improved financial footing reassures investors and allows the company to focus on achieving key milestones in its research pipeline. The company has been selected to present new data on its RTNova systemic virotherapy platform at the prestigious AACR annual meeting in April 2025. Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, is making significant strides in the field of cancer immunotherapy. Known for its innovative approach to antitumor virotherapies, Calidi is focused on harnessing the power of its patented…

TuesdayFeb 25, 2025 10:45 am

How Adageis Simplifies Value-Based Care, Boosting Revenue for Healthcare Providers

Adageis streamlines complex insurance contracts, helping providers maximize reimbursements. The company’s AI-driven solutions reduce administrative burden, freeing up time for patient care. Seamless integration with nearly 100 EHR systems ensures a smooth transition to value-based care models. The company’s fintech approach enhances financial performance, with providers seeing up to $75,000 in additional revenue. Adageis projects significant growth, expecting to cover 580,000 patient lives by mid-2025. Healthcare is shifting toward value-based care, where providers are reimbursed for patient outcomes rather than the number of procedures performed. While the model promises higher-quality care at lower costs, it also introduces complex reimbursement structures…

TuesdayFeb 25, 2025 10:00 am

2025 eCommerce Trends That Could Be Game Changers for Your Online Business

The worldwide e-commerce market is predicted to expand by 7.8% and reach a market value of $6.5 trillion by the end of this year. As an e-commerce operator, it is in your best interest to leverage the emerging trends so that your business can claim its fair share of this expanding market. We discuss some of those trends below. Social Commerce This is one big trend to watch if you are into e-commerce. Social media as well as other digital channels are the hallmarks in this trend. The concept allows transactions to happen easily between businesses and their target clientele.…

MondayFeb 24, 2025 1:00 pm

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment

According to the American Cancer Society, cancer is the second leading cause of death globally. Oncology drugs are a cornerstone of modern cancer treatment. Calidi Biotherapeutics is a cutting-edge biotechnology company dedicated to developing innovative cancer treatments. Cancer continues to be one of the most significant health challenges of our time, with its global impact growing every year. The increasing number of cancer diagnoses and related deaths underscores the urgent need for more effective treatments, including advanced oncology drugs. Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are at the forefront of research and development, offering hope for millions of patients worldwide.…

FridayFeb 21, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focuses Innovation on Hard-to-Treat Tumors

As cancer numbers grow, Calidi Biotherapeutics is at the forefront of developing novel treatments aimed at improving patient outcomes. Calidi’s platform centers on the use of antitumor virotherapies that selectively infect and kill cancer cells while activating the body’s own immune system to attack the tumor. The company’s therapeutic pipeline targets multiple cancer indications, with a focus on hard-to-treat tumors. Cancer remains a significant global health challenge, with certain types exhibiting particularly high mortality rates. Glioblastoma multiforme (“GBM”), triple-negative breast cancer (“TNBC”), sarcoma and lung cancer are among the most aggressive and deadly forms, necessitating urgent advancements in research and…

FridayFeb 21, 2025 10:00 am

How Adageis’ ProActive Care Approach Puts Patients First While Boosting Provider Revenue

Shifting to value-based care improves patient outcomes and cost-effective provider efficiency. Adageis’ ProActive Care shifts focus from reactive treatment to preventive, patient-centered care, with AI-driven analytics identifying high-risk patients and addressing care gaps. Patients receive more personalized, effective treatment, rather than a volume treatment driven approach. Better patient outcomes lead to reduced hospitalizations and cost savings, while increased cost monitoring and efficiency for providers supports increased revenue and net income potential. For many patients, the American healthcare system often feels rushed, transactional and fragmented. Doctors have limited time, and treatment decisions can be driven by billing structures rather than patient…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Pioneers Systemic Virotherapy with RTNova Platform

Clene Inc. (NASDAQ: CLNN) to Highlight Latest Achievements, Next Steps for CNM-Au8(R), at Q1 Virtual Investor Summit on March 11

Clene Inc. (NASDAQ: CLNN) Leverages APST’s NfL Database to Support FDA-Recommended Analyses for ALS Drug

Adageis Drives Value-Based Care Transition as Healthcare Switches from Artificial General Intelligence to Specific Use Cases

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth with Strengthened Financial Position and Cutting-Edge Research

How Adageis Simplifies Value-Based Care, Boosting Revenue for Healthcare Providers

2025 eCommerce Trends That Could Be Game Changers for Your Online Business

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focuses Innovation on Hard-to-Treat Tumors

How Adageis’ ProActive Care Approach Puts Patients First While Boosting Provider Revenue

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search